Welcome to our dedicated page for Marimed SEC filings (Ticker: MRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MariMed Inc. (MRMD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, quarterly updates, and annual reports filed with the U.S. Securities and Exchange Commission. As a multi-state cannabis operator and cannabis consumer packaged goods company, MariMed uses these filings to report on its financial condition, operating performance, and material events.
Investors can review documents such as Form 8-K current reports, where MariMed furnishes press releases announcing quarterly results and other significant developments. These filings typically reference revenue, gross margin, net income or loss, and non-GAAP measures like Adjusted EBITDA and non-GAAP gross margin, along with management’s discussion of how these metrics are used to evaluate the business.
Through its periodic reports, MariMed also describes risks, uncertainties, and factors that could affect future performance, including changes in customer spending, regulatory approvals, and integration of acquired operations. Forward-looking statements in these filings are accompanied by cautionary language directing readers to additional risk discussions in the company’s reports.
On Stock Titan, each new MariMed filing is captured from the SEC’s EDGAR system and paired with AI-powered summaries that highlight key points, such as updates to financial results, explanations of non-GAAP metrics, and descriptions of material events. Users can quickly scan these summaries, then open the full filing for deeper review. This page also helps track items like insider and executive-related disclosures when they are reported on SEC forms, giving a structured view of MariMed’s regulatory reporting history.
MariMed Inc. President and CEO Jon R. Levine, who is also a director and 10% owner, reported insider equity activity dated 12/15/2025. On that date, 89,859 restricted stock units vested and converted one-for-one into shares of common stock at a stated price of $0, increasing his direct holdings.
To satisfy related tax withholding obligations, 26,374 shares of common stock were withheld by MariMed at $0.1071 per share. Following these entries, Levine directly holds 21,136,200 MariMed common shares and has indirect beneficial ownership of 6,684,640 shares held by the Jon Levine Family Trust for the benefit of his spouse and children, which he formally disclaims for Section 16 purposes.
MariMed Inc. director Edward Gildea reported the conversion of restricted stock units into common stock. On December 15, 2025, 247,385 restricted stock units were settled into 247,385 shares of MariMed common stock at a stated price of $0 per share under transaction code M.
After this transaction, Gildea directly owned 905,208 shares of MariMed common stock. The RSUs were originally granted on December 5, 2025 and vested in full on December 15, 2025 as payment in stock instead of cash for a portion of his fees for serving on the company’s board of directors.
MariMed Inc.'s Chief Commercial Officer Ryan Crandall reported stock-based compensation and related share movements dated December 15, 2025. He converted previously granted restricted stock units (RSUs) into 62,902 shares of common stock at a stated price of $0, and 18,462 shares were withheld to cover tax obligations, leaving him with 867,515 common shares held directly after the transactions.
On the same date, Crandall received a new grant of 1,000,000 RSUs, each convertible into one share of MariMed common stock. These RSUs were issued in lieu of a cash salary increase tied to his promotion to Chief Commercial Officer and will vest in four equal installments on June 15, 2026, December 15, 2026, June 15, 2027 and December 15, 2027.
MariMed Inc. director David R. Allen reported the conversion of restricted stock units into 176,389 shares of common stock on December 15, 2025. The transaction is shown as an acquisition at a price of $0, reflecting the settlement of equity awards rather than a cash purchase.
After this transaction, Allen directly beneficially owns 476,144 shares of MariMed common stock. The RSUs converted on a one-for-one basis, were granted on December 5, 2025, and vested in full on December 15, 2025. They were granted in lieu of cash as payment for a portion of his fees for serving on MariMed’s board of directors.
MariMed Inc.'s Chief Operating Officer Timothy Shaw reported recent stock transactions. On December 12, 2025 he purchased 45,455 shares of common stock at $0.1071 per share. On December 15, 2025, 81,772 restricted stock units vested and converted into common shares, and 24,001 shares were withheld by the company to satisfy tax withholding obligations at $0.1071 per share.
After these transactions, he directly beneficially owned 9,294,541 shares of MariMed common stock. An additional 2,000,000 shares are held indirectly through the Shaw Family Trust for the benefit of his children, for which he disclaims beneficial ownership, and no restricted stock units remain unvested under the May 23, 2025 grant.
MariMed Inc.'s Chief Commercial Officer reported routine equity compensation activity. On 12/08/2025, 54,000 restricted stock units (RSUs) converted into the same number of shares of common stock at an exercise price of $0, increasing his directly held shares to 838,925.
On the same date, 15,850 shares of common stock were withheld by MariMed at a price of $0.0824 per share to cover tax obligations related to the RSU vesting, leaving the officer with 823,075 shares held directly after these transactions. The RSUs convert to common stock on a one-for-one basis.
The filing notes that these RSUs were originally granted on June 8, 2023, and that the remaining 54,000 RSUs from this grant are scheduled to vest on June 8, 2026, under an award agreement between MariMed and the reporting officer.
MariMed Inc. director equity compensation update: Director Edward Gildea reported receiving 247,385 restricted stock units (RSUs) of MariMed Inc. common stock on December 5, 2025. These RSUs convert to common shares on a one-for-one basis and are scheduled to vest in full on December 15, 2025 under the terms of his award agreement with the company. The filing states that the RSUs were granted in lieu of cash for a portion of his fees for serving on the Board of Directors. Following this grant, Gildea is shown as beneficially owning 657,823 shares of MariMed common stock directly, and 247,385 derivative securities in the form of RSUs.
MariMed Inc. director David R. Allen reported an equity compensation grant in the form of restricted stock units (RSUs). On December 5, 2025, he received 176,389 RSUs, each of which converts into one share of MariMed common stock on a one-for-one basis. These RSUs were granted in lieu of cash for a portion of his fees for serving on the company’s Board of Directors.
The RSUs vest in full on December 15, 2025, according to the award agreement between MariMed and Allen. After this grant, he directly beneficially owned 299,755 shares of MariMed common stock and 176,389 RSUs, all held directly.
MariMed Inc. director reports new stock-based compensation grant
A MariMed Inc. (MRMD) director filed a Form 4 disclosing an award of 166,985 restricted stock units (RSUs) on December 5, 2025. Each RSU converts into one share of MariMed common stock, and the award vests in full on December 15, 2025 under the terms of the award agreement. The RSUs were granted in lieu of cash for a portion of the director’s board fees, meaning the director chose to receive equity instead of part of the normal cash compensation. Following this grant, the director reports 315,686 shares of common stock held directly and 166,985 RSUs directly beneficially owned. This filing highlights ongoing use of equity-based compensation to align director pay with company performance.
MariMed Inc. (MRMD) reported an insider equity transaction by its Chief Commercial Officer, Ryan Crandall. On 11/29/2025, Crandall exercised 75,000 restricted stock units (RSUs), which converted into an equal number of common shares at an exercise price of $0 per share. RSUs are a form of stock-based compensation that turn into common stock as they vest.
To cover tax withholding tied to this vesting, 22,013 common shares were withheld at a price of $0.0896 per share. After these transactions, Crandall beneficially owned 784,925 shares of MariMed common stock directly. The RSUs exercised came from a grant originally made on November 29, 2024, with the remaining RSUs from that grant scheduled to vest in four equal installments on May 29, 2026, November 29, 2026, May 29, 2027 and November 29, 2027.